Overview

Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the IOP-lowering efficacy of bimatoprost 0.03% in patients found to be low-responders to latanoprost therapy.
Phase:
Phase 4
Details
Lead Sponsor:
Innovative Medical
Treatments:
Bimatoprost
Latanoprost